Full text is available at the source.
Abstract
Utilization patterns of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with a history of cancer remain largely unexplored.
- GLP-1 RAs are commonly prescribed for managing type 2 diabetes.
- Limited guidance exists for using GLP-1 RAs in patients with a cancer history.
- Understanding these patterns could inform treatment decisions for this patient population.
Simplified